Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Afsar Ali Mian"'
Autor:
Chunqiu Zhao, Fawad Ur Rehman, Sana Shaikh, Rida e Maria Qazi, Zahra Sajid, Afsar Ali Mian, Nongyue He
Publikováno v:
Smart Materials in Medicine, Vol 4, Iss , Pp 313-336 (2023)
Nanoscale metal is considered the backbone of biomedical nanotechnology. Recently, there has been an exponential increase in nanoscale materials’ biomedical applications. These nanomaterials have mainly been employed in drug delivery systems, prost
Externí odkaz:
https://doaj.org/article/3cf2aa3bb13f4df0baa05eb6b26b3c89
Autor:
Afsar Ali Mian, Usva Zafar, Syed Muhammad Areeb Ahmed, Oliver Gerhard Ottmann, El-Nasir M A Lalani
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 1016-1027 (2021)
Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and ponatinib have significantly improved the life expectancy of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) patients; however, resistance to TKIs r
Externí odkaz:
https://doaj.org/article/c89ed034f8fc4dd9a60bfeb6318d1115
Autor:
Rida e Maria Qazi, Zahra Sajid, Chunqiu Zhao, Irfan Hussain, Fizza Iftikhar, Muhammad Jameel, Fawad Ur Rehman, Afsar Ali Mian
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 13, p 10477 (2023)
Exosomes are nanoscale extracellular vesicles which regulate intercellular communication. They have great potential for application in nanomedicine. However, techniques for their isolation are limited by requirements for advanced instruments and cost
Externí odkaz:
https://doaj.org/article/ac005f5a03f241e5a7d369df7df70033
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Acute promyelocytic leukemia (APL) is a subset of acute myeloid leukemia (AML) which is characterized by the fusion of promyelocytic leukemia PML and retinoic acid receptor- alpha (RAR-alpha) genes. All-trans retinoic acid (ATRA)
Externí odkaz:
https://doaj.org/article/076e08a4f7994ba9beda9c3ebf5fc5a7
Autor:
Anahita Rafiei, Afsar Ali Mian, Claudia Döring, Anna Metodieva, Claudia Oancea, Frederic B Thalheimer, Martin Leo Hansmann, Oliver Gerhard Ottmann, Martin Ruthardt
Publikováno v:
PLoS Genetics, Vol 11, Iss 4, p e1005144 (2015)
The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia. The t(9;22) is a recipro
Externí odkaz:
https://doaj.org/article/e656123223284eafa41f1d7b430b3911
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 9, Pp 1016-1027 (2021)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, and ponatinib have significantly improved the life expectancy of Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) patients; however, resistance to TKIs r
Publikováno v:
Cancer Research. 83:4746-4746
Background: In humans, the β-like globin genes are encoded from a single locus comprising five globin genes (ε-, Gγ-, Aγ-, δ-, and β-globin in sequence) and their expression is under developmental control. The γ-globin genes (Gγ- and Aγ-) ar
Publikováno v:
Cancer Research. 83:833-833
Background: Exosomes are extracellular vesicles having less than 200 nm size, secreted extracellularly by almost all types of cells. They regulate intercellular communication by delivering RNAi, proteins, viruses, and soluble factors as inherited pay
Autor:
Hammad Hassan, Sarah Yousuf, Syed Muhammad Ahmed, Karim Ruknuddin, Hadiqa Raees, Sadia Habib, Fizza Iftikhar, Afsar Ali Mian, Elnasir Lalani
Publikováno v:
Cancer Research. 83:4040-4040
Background: Asciminib an allosteric tyrosine kinase inhibitor (TKI) was recently approved by the FDA for managing Philadelphia positive chronic myeloid leukemia (CML) patients in chronic phase who had failed to respond to previous TKIs. In this study
Autor:
Ricardo M. Biondi, Claudia Chiriches, Elizabeh Eshel, Oliver G. Ottmann, Larissa Pietsch, Dally Najib, Isabella Haberbosch, Martin Ruthardt, Oliver Hantschel, Abed Agbarya, Jamal Mahajna, Afsar Ali Mian, Hazem Khamaisie
Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome–positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common “gatekeeper” mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::065257f72ea9b48d1b46e14465a4f7c1
https://orca.cardiff.ac.uk/id/eprint/136955/8/Mian2021_Article_CrizotinibActsAsABL1InhibitorC.pdf
https://orca.cardiff.ac.uk/id/eprint/136955/8/Mian2021_Article_CrizotinibActsAsABL1InhibitorC.pdf